Key result
Oral levosimendan did not improve the Patient Journey composite score compared to placebo in patients with severe chronic heart failure (p=0.567), despite improvements in quality of life and NT-proBNP.
Why the study?
Does oral levosimendan improve the Patient Journey composite in patients with severe chronic heart failure?
RCT (n=307)
double-blind
randomly assigned
Does oral levosimendan improve the Patient Journey composite in patients with severe chronic heart failure?
p-value: p=0.567
Oral levosimendan did not improve the primary composite clinical endpoint in severe chronic heart failure, despite improvements in quality of life and NT-proBNP.
No takes yet. Share an insight, caveat, or question.
Does not support oral levosimendan for clinical outcomes in severe chronic HF; challenges translation of QoL and NT-proBNP gains into meaningful benefit.
Nieminen et al. (2008) conducted an RCT in severe chronic heart failure (CHF) (n=307). oral levosimendan vs. placebo was evaluated on Patient Journey, a composite consisting of repeated symptom assessments, worsening heart failure and mortality during 60 days (p=0.567). Oral levosimendan did not improve the Patient Journey composite score compared to placebo in patients with severe chronic heart failure (p=0.567), despite improvements in quality of life and NT-proBNP.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: